LncRNA ZNF593-AS offers hope for heart disease treatment

The research presented in the article delves into the regulatory role of the long non-coding RNA (lncRNA) ZNF593-AS in cardiac hypertrophy and myocardial remodeling, processes that are pivotal in the progression of heart failure and other cardiovascular diseases. The study uncovers how ZNF593-AS exerts its inhibitory effects by upregulating the expression of Mitofusin 2 (Mfn2), a protein known for its role in the regulation of mitochondrial dynamics and cellular metabolism.

Roche to launch new CGM in Europe in ‘coming weeks’

Roche plans to launch its first continuous glucose monitor (CGM) in Europe “in the coming weeks,” Sérgio Moreiras, the company’s international business leader for continuous

September 12, 2024

Private equity activity in the pharmaceutical industry in Germany increased in 2023

In value terms, private equity deal activity in Germany decreased by 38% in Q2 2023 compared with the previous quarter’s total of $435m. Related deal

August 1, 2023

Hepatitis B market is ripe for treatment development, says Aligos CEO – Pharmaceutical Technology

As the hepatitis virus infectious burden remains an issue, Aligos Therapeutics CEO highlights the opportunity for pharmaceutical companies to find success by offering new treatment

August 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.